ASTRA Central and Eastern European Women’s Network for Sexual and Reproductive Rights and Health

May 21 2015

ASTRA Network invites to a Public Hearing on

“Barriers in access to reproductive health goods and services"

under the auspices of the European Parliament Working Group on Reproductive Health, HIV/AIDS and Development and hosted by EPWG Co-Chairs: MEP Sophie in 't Veld and MEP Heidi Hautala

Thursday, June 4th, 2015

12:00 sandwich lunch

12.30 - 14.30 event

Meeting room ASP 1E1, Altiero Spinelli Building

European Parliament, Brussels

 

SPEAKERS:

Opening speech by MEP Sophie in 't Veld

Marta Szostak, ASTRA Network Secretariat

Adriana Lamackova, Center for Reproductive Rights

Milena Kadieva, Gender Alternatives Foundation

Irina Costache, A.L.E.G.

Nataša Bijelić, CESI - Centar za edukaciju, savjetovanje i istraživanje

Neil Datta, The European Parliamentary Forum on Population and Development

Closing remarks by MEP Heidi Hautala

 

  Access the event flyer in pdf

Facebook event

 

May 18 2015

WHO: BREAKING NEWS!

Misoprostol for treating PPH included in the Model List of Essential Medicines

The World Health Organization has just released the Report of the 20th WHO Expert Committee on the Selection and Use of Essential Medicines. The Report recommends that misoprostol be included in the Model List of Essential Medicines (EML) for the additional indication of treating post-partum haemorrhage (in addition to preventing PPH) when oxytocin is not available or cannot be used safely. This means that health care providers who are not qualified to give oxytocin injections or where oxytocin is not availble, e.g. in community-based facilities can now provide misoprostol to treat as well as to prevent post-partum haemorrhage.

The Report states: "Two applications related to misoprostol were considered by the Expert Committee. The Committee recommended listing misoprostol for the additional indication of post-partum hemorrage, when oxytocin is not available or cannot be used safely, but it did not recommend deletion of misoprostol for the post-partum hemorrage prevention indication. The Committee noted that no new clinical trial data to support deletion has been presented compared to the same application in 2013."

The Committee also recommended the addition of three new contraceptive products to the EML: the etonogestrel-releasing implant, the levonorgestrel-releasing intrauterine system and the progesterone contraceptive vaginal ring.

***

Report of the 20th WHO Expert Committee on the Selection and Use of Essential Medicines, May 2015:

http://www.who.int/medicines/publications/essentialmedicines/Executive-Summary_EML-2015_7-May-15.pdf

All applications and documents reviewed by the Expert Committee:

http://www.who.int/selection_medicines/committees/expert/20/en/

2015 WHO Model List of Essential Medicines

May 14 2015

EU governments met to coordinate for the post-2015 negotiation session (as well as the Council Conclusions on the “Global Partnership for Poverty Eradication and Sustainable Development after 2015”, which are also to include a section on accountability) from 18 to 22 May. European civil society came together to address this important meeting. The joint ASTRA, EuroNGOs, Countdown 2015 and IPPF EN position paper is available HERE.

May 11 2015

In Bulgaria, according to statistics[1], the birth rate among girls aged 15-19 is 41 births in 1000 women in reproductive age, compared to other European countries like Germany - 8 births per 1,000, France - 10.7 and Spain 9.1[2]. There is also a stable tendency for age decline, as in the end of 2013 the number of girls aged 11/12-14 who have become mothers was 298 (out of 860 for the age bracket 12-18 years[3]). These facts place Bulgaria on the first place in Europe in pregnancies among girls aged 12-18. Our country is also a leader in abortions among minors[4] which means that abortion has been regarded as a method of contraception.

Read more...
May 06 2015

ASTRA Network will hold a public hearing on the issue of “Barriers in access to reproductive health goods and services". It will be held under the auspices of the European Parliament Working Group on Reproductive Health HIV/AIDS and Development, especially MEPs Sophie in’t Veld and Heidi Hautala. The hearing will be held on June 4th from 12.30 to 14.30 in the premises of the European Parliament in Brusels.

More information will be available soon on ASTRA’s website.

Page 1 of 59

EU

CoE

UN

HRC

Sign up for Bulletin

Twitter Astra